A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.

ABSTRACT: A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for minimal residual disease assessment of cell clonotypes with mutations of NPM1, IDH1/2 and/or FLT3-single nucleotide variants. For clinical validation, 106 follow-up samples from 63 patients in complete remission were studied by sequencing, evaluating the level of mutations detected at diagnosis. The predictive value of minimal residual disease status by sequencing, multiparameter flow cytometry, or quantitative polymerase chain reaction analysis was determined by survival analysis. The sequencing

SUBMITTER: Onecha E 

PROVIDER: S-EPMC6355493 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature